Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States.
As of 2014 the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017.
In 2017 the phase III KEYNOTE-252/ECHO-301 trial (also with pembrolizumab) reported good results for epacadostat (INCB024360) in some types of melanoma.
Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.
According to wikipedia